Roka Bioscience

Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. The Atlas System represents a new tier of molecular rapid pathogen testing, offering automation and technology that bring true walk-away convenience and workflow advantages to the laboratory. Its focus on food safety Roka delivers accurate and reliable test results for food pathogens regardless of sample type.


Company Growth (employees)
Type
Public
HQ
Warren, US
Founded
2009
Size (employees)
90 (est)
Roka Bioscience was founded in 2009 and is headquartered in Warren, US

Key People at Roka Bioscience

Paul G. Thomas

Paul G. Thomas

Chairman of the Board
David R. Patterson

David R. Patterson

Vice President of Manufacturing Operations
Lars Boesgaard

Lars Boesgaard

Vice President, CFO

Roka Bioscience Office Locations

Roka Bioscience has an office in Warren
Warren, US (HQ)
20 Independence Boulevard

Roka Bioscience Data and Metrics

Roka Bioscience Financial Metrics

Roka Bioscience's revenue was reported to be $2 m in Q1, 2017
USD

Revenue (Q1, 2017)

2 m

Gross profit (Q1, 2017)

(72 k)

Gross profit margin (Q1, 2017), %

(4%)

EBIT (Q1, 2017)

(7.3 m)

Market capitalization (15-Aug-2017)

11.4 m

Cash (31-Mar-2017)

1.3 m
Roka Bioscience's current market capitalization is $11.4 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

5.1 m6 m7.2 m

Revenue growth, %

18%21%

Cost of goods sold

8 m

Gross profit

(732 k)

Gross profit Margin, %

(10%)

R&D expense

7.3 m

General and administrative expense

17.7 m

Operating expense total

36.6 m41.3 m36.7 m

EBIT

(31.6 m)(35.3 m)(29.5 m)

EBIT margin, %

(625%)(590%)(407%)

Interest expense

(1.6 m)

Interest income

(1.6 m)

Pre tax profit

(31 m)

Income tax expense

(245 k)

Net Income

(32.2 m)(36.6 m)(30.8 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

1.5 m1.5 m1.6 m1.8 m1.9 m2 m

Cost of goods sold

1.8 m1.7 m2.1 m2 m2 m2.1 m

Gross profit

(289 k)(164 k)(450 k)(224 k)(99 k)(72 k)

Gross profit Margin, %

(20%)(11%)(28%)(12%)(5%)(4%)

R&D expense

1.9 m2.1 m2 m1.5 m1.6 m1.4 m

General and administrative expense

5.4 m4.9 m4.4 m4.5 m4.5 m4.9 m

Operating expense total

7.3 m7 m6.4 m6 m6.2 m6.3 m

EBIT

(8.5 m)(8.1 m)(7.8 m)(7.2 m)(7.2 m)(7.3 m)

EBIT margin, %

(581%)(536%)(477%)(392%)(382%)(358%)

Interest expense

(718 k)(404 k)(417 k)(404 k)(379 k)(311 k)

Interest income

(718 k)(404 k)(417 k)(404 k)(379 k)(311 k)

Pre tax profit

(9.2 m)(8.5 m)(8.2 m)(7.6 m)(7.6 m)(7.6 m)

Income tax expense

4 k4 k(2 k)2 k16 k
USDFY, 2014FY, 2015FY, 2016

Cash

7.5 m3.4 m8.8 m

Accounts Receivable

375 k

Inventories

4.9 m3.9 m3.7 m

Current Assets

51.4 m42.1 m35.1 m

PP&E

12.2 m9.8 m7.8 m

Goodwill

360 k

Total Assets

103.8 m74.6 m61.8 m

Accounts Payable

1.1 m675 k1.3 m

Current Liabilities

13.9 m18.6 m15.1 m

Total Liabilities

25 m

Additional Paid-in Capital

212.1 m214.6 m245.1 m

Retained Earnings

(133 m)(169.6 m)(208.1 m)

Total Equity

36.9 m

Financial Leverage

1.7 x
USDQ1, 2017

Cash

1.3 m

Inventories

4.1 m

Current Assets

23.3 m

PP&E

7.4 m

Total Assets

48.7 m

Accounts Payable

758 k

Current Liabilities

14.9 m

Additional Paid-in Capital

245.4 m

Retained Earnings

(215.7 m)

Total Equity

29.5 m

Financial Leverage

1.6 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(32.2 m)(36.6 m)(30.8 m)

Depreciation and Amortization

4.2 m6.2 m5.8 m

Accounts Receivable

(220 k)(122 k)(207 k)

Inventories

(2.8 m)690 k(638 k)

Accounts Payable

(465 k)4.1 m(362 k)

Cash From Operating Activities

(25.2 m)(4.1 m)(22.8 m)

Purchases of PP&E

(171 k)(277 k)

Cash From Investing Activities

(60.5 m)20.1 m12.4 m

Cash From Financing Activities

58.7 m(393 k)15.8 m

Interest Paid

688 k647 k553 k
USDQ2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Depreciation and Amortization

937 k937 k939 k939 k939 k937 k

Inventories

4.7 m4.9 m4.5 m4.4 m3.9 m3.8 m3.9 m4.1 m

Accounts Payable

882 k868 k495 k413 k610 k582 k1.1 m758 k
USDY, 2017

Revenue/Employee

22.6 k

Financial Leverage

1.6 x

Roka Bioscience Market Value History

Traffic Overview of Roka Bioscience

Roka Bioscience Online and Social Media Presence

Roka Bioscience Company Life and Culture

You may also be interested in